Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 21.23 CNY -0.66%
Market Cap: 60.5B CNY
Have any thoughts about
Shanghai Pharmaceuticals Holding Co Ltd?
Write Note

Net Margin
Shanghai Pharmaceuticals Holding Co Ltd

1.5%
Current
2%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.5%
=
Net Income
4B
/
Revenue
272.4B

Net Margin Across Competitors

Country CN
Market Cap 60.9B CNY
Net Margin
1%
Country US
Market Cap 77.7B USD
Net Margin
1%
Country US
Market Cap 48.9B USD
Net Margin
1%
Country US
Market Cap 48.4B USD
Net Margin
1%
Country US
Market Cap 30.1B USD
Net Margin
1%
Country US
Market Cap 9.3B USD
Net Margin
3%
Country CN
Market Cap 65B CNY
Net Margin
8%
Country KR
Market Cap 12.2T KRW
Net Margin
7%
Country CN
Market Cap 65.4B HKD
Net Margin
1%
Country IT
Market Cap 5.5B EUR
Net Margin
7%
Country DE
Market Cap 5B EUR
Net Margin
-5%
No Stocks Found

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
60.5B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a key player in China's healthcare sector, emerged from its roots in the early 1990s to become one of the largest pharmaceutical companies in the country. It operates in two main segments: pharmaceutical manufacturing and distribution. With a strong portfolio of generic and branded medications, the company leverages its extensive distribution network to reach hospitals and pharmacies across China. Shanghai Pharmaceuticals focuses on innovative drug development and has made significant strides in research, particularly in oncology and high-demand therapeutic areas, positioning itself well for growth in a rapidly evolving market. For investors, Shanghai Pharmaceuticals represents a compelling opportunity, not only due to its robust domestic market but also its potential for international expansion. The company's commitment to R&D, alongside strategic partnerships with global pharmaceutical firms, underscores its forward-thinking approach. Additionally, as China's healthcare reforms push for improved access to medicines, Shanghai Pharmaceuticals stands to benefit from increased demand. With a seasoned management team and a solid track record of consistent revenue growth, investors looking for exposure in the burgeoning Asian pharmaceutical landscape may find Shanghai Pharmaceuticals an attractive addition to their portfolios.

Intrinsic Value
47 CNY
Undervaluation 55%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.5%
=
Net Income
4B
/
Revenue
272.4B
What is the Net Margin of Shanghai Pharmaceuticals Holding Co Ltd?

Based on Shanghai Pharmaceuticals Holding Co Ltd's most recent financial statements, the company has Net Margin of 1.5%.